After the initial report of a striking response to treatment with the ALK inhibitor crizotinib (approved for lung cancers with ALK rearrangements) in a patient suffering from an ALK-rearranged inflammatory myofibroblastic tumor [30], a larger study showed that six of 12 ALK-positive patients (50%) achieved an objective response with crizotinib [188]. Here, ALK is linked to lung carcinoma.